Pain and inflammation are common symptoms experienced by people with rheumatoid arthritis (RA) and osteoarthritis (OA). A recent review of the literature suggested that RA patients are at greater risk of developing pain and inflammation compared with patients who do not have RA (e.g. patients with mild osteoarthritis).1 A recent review of the literature suggests that RA patients are at greater risk of developing pain and inflammation than those who do not have RA.2
To address this gap in knowledge, the aim of this study was to assess the prevalence of pain, inflammation, and joint inflammation in patients with RA and OA compared with a control group of patients without RA. A retrospective, cross-sectional review of medical records of RA patients (n = 9,927) was performed using the International Index of Erectile Function (IIEF) domain. Pain was assessed by a questionnaire, while inflammation was assessed by a questionnaire. The proportion of patients with pain, inflammation, and joint inflammation was significantly higher in the RA group than in the control group (27.5% vs. 12.1%; P < 0.001). The proportion of patients with inflammation was also significantly higher in the RA group compared with the control group (27.6% vs. 13.9%; P < 0.001). The pain and inflammation scores were higher in the RA group compared with the control group (P < 0.001) and significantly more in the RA group compared with the control group and significantly more in the RA group compared with the control group and significantly more in the RA group compared with the control group and significantly more in the RA group compared with the control group.
The results of this analysis were obtained from the IEF-IIEF questionnaire and the IIEF-R. We found that the prevalence of pain and inflammation in patients with RA and OA was significantly higher than in the control group, and that the inflammatory scores in the RA group were higher than in the control group. However, the pain and inflammation scores were significantly lower in the RA group compared with the control group (P < 0.001).
The findings from this analysis were compared with those of a recent systematic review, which suggested that the prevalence of pain and inflammation was higher in patients with RA compared with that of the control group.2 A recent systematic review identified RA patients as being at increased risk of pain and inflammation compared with patients with OA, and that RA patients may have higher pain and inflammation scores compared with those with OA.3
As previously noted, RA patients are at increased risk of developing pain and inflammation.1-5
The IEF-IIEF questionnaire is a validated questionnaire that assesses various aspects of symptoms associated with RA and OA. The IIEF-R is a specific questionnaire that measures the global, global, global and global aspects of pain, inflammation, and joint inflammation. The IIEF-R is a questionnaire that assesses the global, global, global and global and pain-related IIEF-R. In this study, we focused on pain and inflammation in RA and OA patients. We hypothesized that RA patients with arthritis may have higher pain and inflammation compared with those with RA patients with OA.
The study population consisted of RA patients (n = 9,927) who had received an initial diagnosis of RA, or OA, by the American College of Rheumatology (ACR) criteria. These patients were excluded if they had a history of NSAID use (e.g. aspirin, ibuprofen, or naproxen) or had significant gastrointestinal disease (e.g. ulcerative colitis, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, ulcerative colitis, ulcerative colitis, or perforation of the intestine). Patients were excluded if they were diagnosed with Crohn’s disease or inflammatory bowel disease (IBD) or Crohn’s disease (CD); had any history of NSAID use; were taking corticosteroids, including corticosteroids (e.g. prednisone), or had an allergy to aspirin or ibuprofen; or had an active peptic ulcer.
Patients were screened using the following screening tools for RA: the American College of Rheumatology IIEF, the IIEF-R, and the IIEF-R II.2
All RA patients were included in the study. The RA patients were diagnosed using the ACR criteria.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$19.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Healthylife product informationThis is a data release and the data set, including images, is not intended to indicate a specific specific health-related product or health condition. It is solely a representation of the global information and looks at not only the market but the types of products marketed and their use. You should not place undue reliance on the statements in relation to your specific situation. If you have any questions about the data set, please always contact your pharmacist or pharmacist. This does not and should not be used as a substitute for professional medical advice. If you have any questions about the data set, please always contact your doctor or pharmacist.
Healthylife informationThis leads to the important information listed on the image. Although healthylife.com.au contains specific information about your interests, it is not able to provide this information in all circumstances. You should always read the enclosed patient information information leaflet for more information about healthylife.com.au. This information is for your information consider familiarising yourself with the information you are purchasing and would be appalled to refrain from purchasing this product.
Product name and logoHealthylife logo
Healthylife brand name
Healthylife trademarks
Product manufacturer and trade name: Healthylife
Healthylife registered trademark: Bazaar
Copyright (C) 2003 Healthylife. All rights reserved
Wanless PharmacyNo portion of this product may be shipped to customers in the United States, other than as provided by the manufacturer or a contracted wholesaler. This product cannot be compelled or eligible for anybranded usage information. Please consult your doctor or pharmacist for appropriate usage information.
Healthylife caplets USPThis is a prescription medication. Please read the enclosed patient information leaflet before taking this product.
Nutritional informationThis product contains nutritional information. You will be advised that this product contains vitamins, nutrients, and other substances. You should take this product only with a full glass of water.
If you have any questions about the nutritional information contained on your prescription, contact your doctor or pharmacist. You should check the medication's expiration date and not exceed the prescribed dosage.
Lab referenceThis is a product reference for product information. Note: Product references are not intended for use by and certified by the trademark owner or the manufacturer.
Medicine packagingThe primary indication for NSAIDs is in adults.
The dosage of the medicinal product is the same for all the active substances present in the drug, regardless of whether they are oral or intravenous. The usual recommended daily dose is 50 to 200 mg. The amount of drug absorbed through the gastrointestinal tract can be reduced by up to 30% according to the dose. The most common adverse effect is gastrointestinal upset. Gastrointestinal side effects are:
The dosage of the medicinal product is based on the condition and response to the therapeutic effect of the drug. If the condition is not improved by the treatment with the medicinal product, the dosage should be reduced. If a drug is added in the same strength as the medicinal product, the dose should be reduced.
The maximum recommended dose is 600 mg per day. The maximum recommended daily dose is 1,200 mg daily. The maximum daily dose should not exceed 6,200 mg daily. If the effect of the medicinal product is not improved by the treatment with the medicinal product, the dosage should be reduced.
The therapeutic effect of the medicinal product can be achieved with the use of the medicinal product. The maximum recommended daily dose is 2,200 mg daily. The maximum recommended dose is 3,200 mg daily.
The maximum recommended daily dose should not exceed 6,200 mg daily. The maximum recommended dose should not exceed 6,200 mg daily.
The most common adverse effect of the medicinal product is headache. If any of the following effects occur, it is necessary to stop treatment:
If any of the above effects are present, it is necessary to stop treatment.
There are with NSAIDs, including the painkiller paracetamol, analgesics acetylsalicylic acid, and NSAIDs ibuprofen, and anticonvulsants antihistamines, such as diphenhydramine, phenobarbital and cetirizine. The interaction between NSAIDs and the medicinal products may occur in the following ways:
A lot of people think that ibuprofen is the right thing to do, but in the case of, the truth is that it is more effective.
Ibuprofen is available over the counter in most pharmacies in the UK.
The most common recommended dose of ibuprofen is 200mg, which is equal to 4 tablets of 200mg aspirin.
The tablets are then swallowed with a glass of water.
This is usually taken when ibuprofen is not available.
If you have been told that you are not allergic to ibuprofen, you may not be able to swallow the tablets.
A person who is unable to swallow a tablet of ibuprofen should have it taken with food. Alternatively, they can take a tablet of aspirin with food, such as a banana or pineapple.
The medication is taken by mouth.
It is also important that you take it exactly as your doctor has told you.
Ibuprofen is not usually recommended for use in children under the age of 12.
There is a risk of severe allergic reactions to ibuprofen, including anaphylaxis.
Aurobindo Laboratories Inc.
Our team of pharmacists is based in the UK and we are a national pharmacy chain.
You’ll meet with the pharmacist to discuss any questions you may have and we’ll help you get started.
The pharmacy is a private, regulated pharmacy that has been in operation for over 15 years and is available to buy from our local pharmacy.
We are based in the UK and we are a national pharmacy chain.
We are a UK based pharmacy chain, located in London, UK. We work closely with our pharmacists to provide the most convenient and safe way of getting your medicines to you.
Our pharmacy is available to buy from our own online pharmacy.
We are also a leading supplier of medicines and a member of the General Pharmaceutical Council (GPhC).
We are a member of the General Pharmaceutical Council (GPhC) and we have been in business since 1994.
Our service is available 24 hours a day.
We are a leading supplier of medicines and a member of the General Pharmaceutical Council (GPhC).
Our pharmacy is a fully registered company and we are able to supply all medicines on our own.
We are based in the UK and have a wide range of medicines, including all OTC products such as aspirin and ibuprofen, with an emphasis on pain management.
We are a British Pharmacy chain and have a wide range of medicines, including all OTC products such as aspirin and ibuprofen, with an emphasis on pain management.
We offer a wide range of medicines, including all OTC products such as pain relief, cold and flu treatment, and over-the-counter analgesics.
Stade de France Pharmacy